Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Keating

Showing results (301-310 of 436) with videos related to

Pageof 44
Sort By:
Leukemia|April 4, 2008
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanismH Zhang, D Trachootham, W Lu, et al.
Leukemia|August 1, 1994
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinosideH M Ghaddar, W Plunkett, H M Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignanciesD F Kisor, W Plunkett, J Kurtzberg, et al.
Leukemia & Lymphoma|September 24, 1999
Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phaseM Wilhelm, S O'Brien, M B Rios, et al.
Blood Cells|January 1, 1983
Quantitative cytology in leukemia researchB Barlogie, A M Maddox, D A Johnston, et al.
Haematology and Blood Transfusion|January 1, 1990
Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSFE H Estey, H M Kantarjian, M Beran, et al.
American Journal of Hematology|March 1, 1997
Expression profile of MDM-2 proteins in chronic lymphocytic leukemia and their clinical relevanceM A Haidar, H El-Hajj, C E Bueso-Ramos, et al.
Cancer|January 28, 1999
Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literatureA Aguayo, J E Cortes, H M Kantarjian, et al.
Southern Medical Journal|October 1, 1987
Old age: a sign of poor prognosis in patients with chronic myelogenous leukemiaH M Kantarjian, M J Keating, K B McCredie, et al.
Australian and New Zealand Journal of Medicine|June 1, 1982
Retrospective analysis of 158 cases of adult acute leukaemia: factors influencing prognosis and treatment responseE Januszewicz, F C Firkin, C N Chesterman, et al.
Pageof 44

Showing results (301-310 of 436) with videos related to

Sort By:
Pageof 44
Leukemia|April 4, 2008
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanismH Zhang, D Trachootham, W Lu, et al.
Leukemia|August 1, 1994
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinosideH M Ghaddar, W Plunkett, H M Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignanciesD F Kisor, W Plunkett, J Kurtzberg, et al.
Leukemia & Lymphoma|September 24, 1999
Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phaseM Wilhelm, S O'Brien, M B Rios, et al.
Blood Cells|January 1, 1983
Quantitative cytology in leukemia researchB Barlogie, A M Maddox, D A Johnston, et al.
Haematology and Blood Transfusion|January 1, 1990
Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSFE H Estey, H M Kantarjian, M Beran, et al.
American Journal of Hematology|March 1, 1997
Expression profile of MDM-2 proteins in chronic lymphocytic leukemia and their clinical relevanceM A Haidar, H El-Hajj, C E Bueso-Ramos, et al.
Cancer|January 28, 1999
Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literatureA Aguayo, J E Cortes, H M Kantarjian, et al.
Southern Medical Journal|October 1, 1987
Old age: a sign of poor prognosis in patients with chronic myelogenous leukemiaH M Kantarjian, M J Keating, K B McCredie, et al.
Australian and New Zealand Journal of Medicine|June 1, 1982
Retrospective analysis of 158 cases of adult acute leukaemia: factors influencing prognosis and treatment responseE Januszewicz, F C Firkin, C N Chesterman, et al.
Pageof 44